[Clinical results of UFT granule of enteric coating (UFT E granule). Osaka UFT E Granule Study Group].
We carried out a Phase II study by single oral administration of UFT granule of enteric coating (UFT E granule) in 40 patients with breast cancer. One CR and 8 PR cases, of which 34 were evaluable, were obtained, and the response rate was 26.5%.; local 28.6%, lymph node 41.2%, lung 22.2%, bone 14.3%. An average of administration duration was 139 days (28-317 days) for 35 cases. Adverse effects were appeared in 60.0% of the overall, main side effects were anorexia, nausea and vomiting; however, those were not serious. It is concluded that UFT E granule is available for the treatment of breast cancer for long term use.
Taguchi
T
T
Dept. of Oncologic Surgery, Osaka University.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004304:Dosage Forms; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D005641:Tegafur / Q000627:therapeutic use; D014498:Uracil / Q000627:therapeutic use
D004304:Dosage Forms; D005641:Tegafur; D014498:Uracil